A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Pfizer18 enrolled

Overview

This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function. This study will also evaluate the safety and tolerability of CP-690,550.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

Conditions

Hepatic Insufficiency

Interventions

CP-690,550DRUG

Single 10 mg dose of CP-690,550

CP-690,550DRUG

Single 10 mg dose of CP-690,550

CP-690,550DRUG

Single 10 mg dose of CP-690,550

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers who have normal liver function, and subjects who have either mild or moderate liver impairment. Exclusion Criteria: * Subjects with severe liver impairment * Subjects who have weakened immune systems

Locations (1)

Pfizer Investigational Site

South Miami, Florida, United States

Outcomes

Primary Outcomes

Pharmacokinetics of CP-690,550 in subjects with hepatic impairment compared to subjects with normal hepatic function

Time frame: 3 days

Secondary Outcomes

Safety and tolerability of CP-690,550 in subjects with hepatic impairment compared to subjects with normal hepatic function

Time frame: 10-14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.